The major goals of D³ include two complementary studies at diverse urban, suburban, and rural primary care practices within Central Indiana and South Florida that will evaluate the predictive performance, the utility and effectiveness of the Passive Digital Marker, the Quick Dementia Rating Scale (QDRS), and the combined approach (Passive + QDRS) in the early detection of Alzheimer’s disease and related dementia (ADRD).

To conduct a Phase 2 clinical trial of CT1812, a novel disease-modifying compound, in patients with mild to moderate dementia with Lewy bodies (DLB)

To engage, enroll and study American Indians, Alaskan Natives, and Native Hawaiians and Pacific Islanders in novel Alzheimer detection and treatment interventions and encourage biomarker and autopsy program participation

To conduct a population-based dementia screening, validate findings in a longitudinal study of ADRD biomarkers, and establish the potential benefits and harms of dementia screening in a multicultural sample